172 related articles for article (PubMed ID: 17083915)
1. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Noguchi M; Yu D; Hirayama R; Ninomiya Y; Sekine E; Kubota N; Ando K; Okayasu R
Biochem Biophys Res Commun; 2006 Dec; 351(3):658-63. PubMed ID: 17083915
[TBL] [Abstract][Full Text] [Related]
2. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
[TBL] [Abstract][Full Text] [Related]
3. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
Stecklein SR; Kumaraswamy E; Behbod F; Wang W; Chaguturu V; Harlan-Williams LM; Jensen RA
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13650-5. PubMed ID: 22869732
[TBL] [Abstract][Full Text] [Related]
5. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
[TBL] [Abstract][Full Text] [Related]
6. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.
Dungey FA; Caldecott KW; Chalmers AJ
Mol Cancer Ther; 2009 Aug; 8(8):2243-54. PubMed ID: 19671736
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.
Zhang T; Li Y; Zhu Z; Gu M; Newman B; Sun D
Mol Pharm; 2010 Oct; 7(5):1576-84. PubMed ID: 20669973
[TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
10. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition.
Enomoto A; Fukasawa T; Takamatsu N; Ito M; Morita A; Hosoi Y; Miyagawa K
Eur J Cancer; 2013 Nov; 49(16):3547-58. PubMed ID: 23886587
[TBL] [Abstract][Full Text] [Related]
11. Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line.
Woo JK; Jang JE; Kang JH; Seong JK; Yoon YS; Kim HC; Lee SJ; Oh SH
Mol Cancer Ther; 2017 Jul; 16(7):1355-1365. PubMed ID: 28336809
[TBL] [Abstract][Full Text] [Related]
12. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
[TBL] [Abstract][Full Text] [Related]
13. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
Yao Q; Weigel B; Kersey J
Clin Cancer Res; 2007 Mar; 13(5):1591-600. PubMed ID: 17332306
[TBL] [Abstract][Full Text] [Related]
14. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells.
Paduano F; Villa R; Pennati M; Folini M; Binda M; Daidone MG; Zaffaroni N
Mol Cancer Ther; 2006 Jan; 5(1):179-86. PubMed ID: 16432177
[TBL] [Abstract][Full Text] [Related]
15. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
16. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
17. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
[TBL] [Abstract][Full Text] [Related]
19. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
Banerji U; Sain N; Sharp SY; Valenti M; Asad Y; Ruddle R; Raynaud F; Walton M; Eccles SA; Judson I; Jackman AL; Workman P
Cancer Chemother Pharmacol; 2008 Oct; 62(5):769-78. PubMed ID: 18193424
[TBL] [Abstract][Full Text] [Related]
20. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
